These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 33173385)
1. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec. Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385 [TBL] [Abstract][Full Text] [Related]
2. Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer. Mooradian MJ; Cai L; Wang A; Qiao Y; Chander P; Whitaker RM JAMA Netw Open; 2024 Apr; 7(4):e247542. PubMed ID: 38648057 [TBL] [Abstract][Full Text] [Related]
3. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R. Filippi AR; Bar J; Chouaid C; Christoph DC; Field JK; Fietkau R; Garassino MC; Garrido P; Haakensen VD; Kao S; Markman B; McDonald F; Mornex F; Moskovitz M; Peters S; Sibille A; Siva S; van den Heuvel M; Vercauter P; Anand S; Chander P; Licour M; de Lima AR; Qiao Y; Girard N ESMO Open; 2024 Jun; 9(6):103464. PubMed ID: 38833971 [TBL] [Abstract][Full Text] [Related]
4. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913 [TBL] [Abstract][Full Text] [Related]
5. Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results. Verschueren MV; Dijs T; Gulikers JL; Veelen AV; Croes S; Hendriks LE; Smit AA; Bloem LT; Egberts AC; van de Garde EM; Peters BJ Immunotherapy; 2023 Aug; 15(11):839-851. PubMed ID: 37291888 [TBL] [Abstract][Full Text] [Related]
6. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Bruni A; Scotti V; Borghetti P; Vagge S; Cozzi S; D'Angelo E; Giaj Levra N; Fozza A; Taraborrelli M; Piperno G; Vanoni V; Sepulcri M; Trovò M; Nardone V; Lattanzi E; Bou Selman S; Bertolini F; Franceschini D; Agustoni F; Jereczek-Fossa BA; Magrini SM; Livi L; Lohr F; Filippi AR Front Oncol; 2021; 11():744956. PubMed ID: 34650927 [TBL] [Abstract][Full Text] [Related]
7. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada. Seung SJ; Hurry M; Walton RN; Evans WK Curr Oncol; 2020 Aug; 27(4):e354-e360. PubMed ID: 32905267 [TBL] [Abstract][Full Text] [Related]
9. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre. Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059 [TBL] [Abstract][Full Text] [Related]
10. Treatment of unresectable stage III NSCLC: Real world cohort study and literature review. Verfaillie S; Lambrecht M; Berkovic P; Dooms C; Nackaerts K; Van de Velde AS; Vansteenkiste J; Wauters E Cancer Treat Res Commun; 2023; 36():100727. PubMed ID: 37307680 [TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study. Horinouchi H; Atagi S; Oizumi S; Ohashi K; Kato T; Kozuki T; Seike M; Sone T; Sobue T; Tokito T; Harada H; Maeda T; Mio T; Shirosaka I; Hattori K; Shin E; Murakami H Cancer Med; 2020 Sep; 9(18):6597-6608. PubMed ID: 32730697 [TBL] [Abstract][Full Text] [Related]
12. Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study. Park JE; Hong KS; Choi SH; Lee SY; Shin KC; Jang JG; Kwon YS; Park SH; Choi KJ; Jung CY; Eom JS; Kim S; Seol HY; Kim J; Kim I; Park JH; Kim TH; Ahn JH Clin Lung Cancer; 2024 Jun; 25(4):354-364. PubMed ID: 38503590 [TBL] [Abstract][Full Text] [Related]
13. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). Maggiore RJ; Zahrieh D; McMurray RP; Feliciano JL; Samson P; Mohindra P; Chen H; Wong ML; Lafky JM; Jatoi A; Le-Rademacher JG J Geriatr Oncol; 2021 May; 12(4):563-571. PubMed ID: 32950428 [TBL] [Abstract][Full Text] [Related]
14. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy. Moore S; Leung B; Wu J; Ho C J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953 [TBL] [Abstract][Full Text] [Related]
15. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272 [TBL] [Abstract][Full Text] [Related]
16. Concurrent chemoradiotherapy versus radiotherapy alone after induction chemoimmunotherapy for stage III NSCLC patients who did not undergo surgery: a single institution retrospective study. Guan S; Ren K; Zhang X; Yan M; Li X; Zhao L Radiat Oncol; 2023 Jul; 18(1):122. PubMed ID: 37491257 [TBL] [Abstract][Full Text] [Related]
17. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. Jazieh K; Khorrami M; Saad A; Gad M; Gupta A; Patil P; Viswanathan VS; Rajiah P; Nock CJ; Gilkey M; Fu P; Pennell NA; Madabhushi A J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35256515 [TBL] [Abstract][Full Text] [Related]
18. Induction chemoimmunotherapy may improve outcomes of chemoradiotherapy in patients with unresectable stage III NSCLC. Guan S; Zhang S; Ren K; Li X; Li X; Zhao L Front Immunol; 2023; 14():1289207. PubMed ID: 38090575 [TBL] [Abstract][Full Text] [Related]